EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients

BACKGROUND: Cetuximab has demonstrated significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve tumor response in locally advanced rectal cancer patients in recent phase I/II trials. We evaluated functional germl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hu-Lieskovan, Siwen, Vallbohmer, Daniel, Zhang, Wu, Yang, Dongyun, Pohl, Alexander, Labonte, Melissa, Grimminger, Peter P., Hölscher, Arnulf H., Semrau, Robert, Arnold, Dirk, Dellas, Kathrin, Debucquoy, Annelies, Haustermans, Karin, Machiels, Jean-Pascal H., Sempoux, Christine, Rödel, Claus, Bracko, Matej, Velenik, Vaneja, Lenz, Heinz-Josef
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3149732/
https://ncbi.nlm.nih.gov/pubmed/21673069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2666
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares